All In MedTech

Device Trial Radar · NCT02417441

TiLE (Time Lapse Eeva) Clinical Trial

A Phase IV, Prospective, Randomized, Exploratory, Multicenter, Eeva™ Trial (Time Lapse Eeva - TiLE)

Last checked: Nov 19, 2026Latest source record: Jan 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 976 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

976

Actual

Start

Jun 29, 2015

Primary completion

Feb 9, 2017

Study completion Feb 9, 2017

Sponsor

Lead sponsor
Merck KGaA, Darmstadt, GermanyNot on our public-company list
Sponsor type
Industry
First posted
Apr 15, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study was to explore the added value of adjunctive use of Early Embryo Viability Assessment (Eeva) with morphological grading in identifying optimal embryos for transfer.

Conditions

  • Fertility

Interventions

  • EevaDevice

    Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Implantation RateTime frame: Gestational Weeks 5 to 8

Locations

23 sites in 9 countries. Site status is shown where the registry gives one.

  • Mount Sinai Hospital

    Toronto, Canada

  • Cambrian Wellness Centre

    Calgary, Alberta, Canada

  • One Fertility

    Burlington, Ontario, Canada

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.